Hengrui Medicine gains approval for four clinical trials

Jiangsu Hengrui Medicine (SSE: 600276) announced that its subsidiaries, Suzhou Shengdiya and Shanghai Shengdi, have received clinical trial approvals from China's National Medical Products Administration (NMPA) for four drug candidates: SHR-A1811 injection, Bevacizumab injection, Aderbelimab injection, and SHR-8068 injection. The SHR-A1811 injection will undergo a Phase Ib/II clinical trial as a combination therapy for advanced solid tumors. The company reported significant cumulative R&D investments for these projects: approximately ¥940.96 million for SHR-A1811, ¥330.88 million for Bevacizumab injection, ¥784.71 million for Aderbelimab injection, and ¥152.64 million for SHR-8068 injection. The company cautioned that the approval-to-market process involves uncertainty and encourages investors to exercise caution.